Navigation Links
ViroPharma Announces First Quarter 2013 Financial Results
Date:5/1/2013

ntial effect of C1-INH in Refractory Paroxysmal Nocturnal Hemoglobinuria (PNH). ViroPharma plans to continue to conduct both clinical and non-clinical studies to evaluate additional therapeutic uses for its C1 INH product in the future.
  • Maribavir for cytomegalovirus – We are currently enrolling patients into a Phase 2 program to evaluate maribavir for the treatment of CMV infections in transplant recipients.  The program consists of two independent Phase 2 clinical studies that include subjects who have asymptomatic CMV in one trial, and those who have failed therapy with other anti-CMV agents in another trial.  Additional data from these ongoing studies will be provided during today's conference call.
  • VP-20629 for Friedreich's Ataxia (FA) – We expect to initiate a single and repeat dose phase 1 study in patients in 2013.
  • Oral Budesonide for eosinophilic esophagitis (EOE) – We currently have an exclusive option agreement to acquire Meritage Pharma, Incorporated based on predefined terms pending data outcomes from a Phase 2 study and concurrence with the U.S. FDA on an acceptable clinical endpoint for the Phase 3 program.  The Phase 2 study is currently enrolling with data expected in 2014.
  • 2013 Guidance ViroPharma is providing guidance for the year 2013 as a convenience to investors. The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties. For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

    For the year 2013, ViroPharma is providing the following update: 

  • Worldwide net product sales are expected to be $440 to $465 million;  
  • Net North American Cinryze sales are expected to be $390 to $400 million; and
  • Research and development (R&D) and selling, general
    '/>"/>

  • SOURCE ViroPharma Incorporated
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. ViroPharma to Participate in Two December Healthcare Investor Conferences
    2. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
    3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    4. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
    6. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
    7. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
    8. WuXi PharmaTech Announces Third-Quarter 2011 Results
    9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
    10. Spherix Announces Third Quarter Financial Results
    11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... 29, 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ... increased its investment in Green Chemistry and donated more ... last year, the Company announced Monday in its new ... the World? The report comes in ... being a responsible corporate citizen, including recognition for the ...
    (Date:7/29/2014)... G-CON Manufacturing Inc., the standard in design and ... leadership appointment designed to drive the company’s ambitious growth ... Maik Jornitz, Chief Operating Officer of G-Con Manufacturing, has ... the pioneering company through its next phase of market ... and look forward to providing our next generation of ...
    (Date:7/29/2014)... July 29, 2014 Dr. Jason Wendel – ... and named one of the Top 10 Plastic Surgeon Specialists ... skin care products. His complete line includes a Hydration Booster, ... give the face and skin a younger, more radiant appearance ... “Everyone’s skin is different, that is why at Dr. J. ...
    (Date:7/28/2014)... A new method of building materials using light, developed ... day enable technologies that are often considered the realm ... devices. , Although cloaked starships won,t be a ... have developed for constructing materials with building blocks a ... to control the way that light flies through them, ...
    Breaking Biology Technology:Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3G-CON Manufacturing, Inc. Announces Maik Jornitz as President 2Dr. J. J. Wendel Launches New Line of Skin Care Products 2Building 'invisible' materials with light 2
    ... The Netherlands, June 24 The U.S. Department,of Energy,s ... to enable the sale and delivery of an Avantium ... PNNL to,accelerate its catalyst research for infrastructure compatible biofuels ... by Battelle for the U.S. Department of Energy. The,Laboratory ...
    ... New Report Calls for a Broad Ethics of Emerging Technologies ... of synthetic biology will allow researchers to create biological parts ... to re-engineer existing organisms to perform novel and beneficial tasks. ... to addressing ethical and social issues is called for, especially ...
    ... WA, and VANCOUVER, June 24 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... the company has reached an agreement with the U.S. ... assessment process (SPA) on an amendment to the design ... lead product candidate targeting castrate resistant prostate cancer (CRPC). ...
    Cached Biology Technology:Avantium to Deliver Flowrence System to Pacific Northwest National Laboratory (PNNL), USA 2Does Synthetic Biology Need Synthesized Ethics? 2Does Synthetic Biology Need Synthesized Ethics? 3OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 2OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 3OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 4OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 5
    (Date:7/29/2014)... researchers have developed an easier method to create ... work involved in diagnosing diseases. , DNA linked ... strong partnership that can be used in diagnostic ... which tag proteins with DNA can be ... and visualisation of biological material. The method also ...
    (Date:7/29/2014)... There,s some good news for parents of preterm babies ... that by the time they become teenagers, the brains of ... born at term. , A study conducted by the University,s ... as the preterm child experiences no brain injury in early ... as good as their term-born peers. , However, the results ...
    (Date:7/28/2014)... already approved by the U.S. Food and Drug Administration ... of certain bacterial pathogens inside human cells, including those ... The findings, published in mBio , the online ... a new way of identifying non-antibiotic drugs that could ... handful of drugs on the list inhibit the growth ...
    Breaking Biology News(10 mins):New method provides researchers with efficient tool for tagging proteins 2Preterm children's brains can catch up years later 2New route to identify drugs that can fight bacterial infections 2
    ... predicted to occur under climate change scenarios has led many ... of wildfires. But a new study in the May issue ... changes in the types of plants growing in an area ... Philip Higuera of Montana State University and his colleagues ...
    ... Orleans, LA Sharell Bindom, a student in the ... will be awarded the Mead Johnson Research Award in ... the 2009 Experimental Biology Meeting April 18-22 in New ... is intended to recognize the graduate student, resident, or ...
    ... do all sorts of work, but a fundamental question has ... "There,s no little man sitting there, putting the protein ... biologist at the USC College of Letters, Arts and Sciences. ... tells them where to go in the cell." In ...
    Cached Biology News:Plants could override climate change effects on wildfires 2Autopilot guides proteins in brain 2
    ... yolk protein Vtg in plasma from juvenile or ... for endocrine disrupting chemicals (EDCs) with estrogenic effects ... accepted screening test for the estrogenic effects of ... kit is a double-antibody immunometric (sandwich) EIA for ...
    ... acid synthetic peptide whose sequence corresponds to residues 115-133 of rat ... terminus): V115 - L - P - S - E ... V - P - N - E - V - L ... been added to facilitate conjugation and is not a part of ...
    ... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
    ... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
    Biology Products: